On November 6, 2017, UACT sent a letter to the US Congress, supporting legislation to permit the United States to negotiate prices for drugs reimbursed by the Medicare program, but also ask the Congress to include language on compulsory licensing of patents, in order to ensure that when there is a dispute over the price, the monopoly is put at risk, rather than the patient.   The letter also asks Congress to enact measures to enhance the transparency of R&D costs and drug manufacturing know-how, and under feasibility studies of delinkage. A copy of the letter is available as a PDF, here , and reads as follows: NovemberRead More →